Early Detection and Treatment of Skin Cancer



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2000 Jul 15;62(2):357-368.

  Patient information: See related handouts on safe-sun guidelines and skin protection, provided by an AAFP staff patient education writer.

The incidence of skin cancer is increasing by epidemic proportions. Basal cell cancer remains the most common skin neoplasm, and simple excision is generally curative. Squamous cell cancers may be preceded by actinic keratoses—premalignant lesions that are treated with cryotherapy, excision, curettage or topical 5-fluorouracil. While squamous cell carcinoma is usually easily cured with local excision, it may invade deeper structures and metastasize. Aggressive local growth and metastasis are common features of malignant melanoma, which accounts for 75 percent of all deaths associated with skin cancer. Early detection greatly improves the prognosis of patients with malignant melanoma. The differential diagnosis of pigmented lesions is challenging, although the ABCD and seven-point checklists are helpful in determining which pigmented lesions require excision. Sun exposure remains the most important risk factor for all skin neoplasms. Thus, patients should be taught basic “safe sun” measures: sun avoidance during peak ultraviolet-B hours; proper use of sunscreen and protective clothing; and avoidance of suntanning.

One in six Americans develops skin cancer at some point. Skin cancer accounts for one third of all cancers in the United States. Most patients with skin cancer develop nonmelanoma skin cancer. This group of cancers includes basal cell carcinoma, the most common neoplasm worldwide, and squamous cell carcinoma. Fortunately, mortality associated with nonmelanoma skin cancer is unusual. However, malignant melanoma accounts for 75 percent of all deaths associated with skin cancer.

Melanoma, the eighth most common malignancy in the United States, is the cancer with the most rapidly increasing incidence. One in 1,500 Americans born in 1935 were likely to develop melanoma, compared with one in 105 persons born in 1993.1 In contrast to nonmelanoma skin cancer, which typically affects older persons, the frequency of melanoma peaks between 20 and 45 years of age.

Mortality rates are higher in men than in women. This higher rate may occur because lesions tend to develop in less easily observed areas, such as the back, in men. Mortality is also increased in blacks for this reason, as is the propensity to develop more aggressive tumors and to be diagnosed at later stages.2

The rising incidence of skin cancer over the past several decades may be primarily attributed to increased sun exposure associated with societal and lifestyle shifts in the U.S. population and to depletion of the protective ozone layer.3

Screening for Skin Cancer

While early detection and treatment of skin cancer can improve patient outcomes,4 convincing data regarding the benefit of mass screening programs are lacking.5 In addition, the ability to identify potentially malignant lesions varies with physician training.6  Thus, except for very high-risk persons with a history of skin cancer or atypical mole syndrome, for whom periodic screening is universally recommended, there is considerable debate about who should be screened, who should perform the screening and how often screening should be performed (Table 1).7  Part of the screening process should include an assessment of patient risk (Table 2).1,812

TABLE 1

Skin Cancer Screening Recommendations from Various Organizations

Organization Recommendation

American Academy of Dermatology; Skin Cancer Foundation; and American Cancer Society

Annual complete skin examination for all patients

Annual complete skin examination for all patients

Age 20 to 39 years: complete skin examination every three years

Age 40 years and older: annual complete skin examination

U.S. Preventive Services Task Force and American Academy of Family Physicians Policy Recommendation for Periodic Health Examination*

There is insufficient evidence to recommend for or against routine complete skin examination.

Physicians should be alert to potentially malignant lesions when examining patients for other reasons, especially when they have risk factors for melanoma, and should consider referring patients with marker lesions (i.e., atypical nevi) to a skin cancer specialist.


*—Available at www.aafp.org/policy/camp/app-d—c.html.

Information from Public Health Service. Office of Disease Prevention and Health Promotion. Clinician's handbook of preventive services. Washington, D.C.: U.S. Department of Health and Human Services, 1994:155.

TABLE 1   Skin Cancer Screening Recommendations from Various Organizations

View Table

TABLE 1

Skin Cancer Screening Recommendations from Various Organizations

Organization Recommendation

American Academy of Dermatology; Skin Cancer Foundation; and American Cancer Society

Annual complete skin examination for all patients

Annual complete skin examination for all patients

Age 20 to 39 years: complete skin examination every three years

Age 40 years and older: annual complete skin examination

U.S. Preventive Services Task Force and American Academy of Family Physicians Policy Recommendation for Periodic Health Examination*

There is insufficient evidence to recommend for or against routine complete skin examination.

Physicians should be alert to potentially malignant lesions when examining patients for other reasons, especially when they have risk factors for melanoma, and should consider referring patients with marker lesions (i.e., atypical nevi) to a skin cancer specialist.


*—Available at www.aafp.org/policy/camp/app-d—c.html.

Information from Public Health Service. Office of Disease Prevention and Health Promotion. Clinician's handbook of preventive services. Washington, D.C.: U.S. Department of Health and Human Services, 1994:155.

TABLE 2

Risk Factors for Skin Cancer

Risk factor Nonmelanoma skin cancer Melanoma

Age

More common with increasing age

Peak frequency in early adulthood, but age-related incidence rises with increasing age.

Chemicals and exposures

Use of coal-tar products, tobacco and psoralens (e.g., PUVA therapy) increase risk.

Radiation exposure increases risk.

Family history

No influence on risk

Occurrence of melanoma in a first- or second-degree relative confers increased risk. Familial atypical mole–melanoma syndrome (FAMMS) confers even higher risk.

Gender

Substantially more common in males

Slight male predominance

Geographic location

Higher incidence in whites living near the equator because of greater ultraviolet (UV) light exposure per unit time

Higher incidence in whites living near the equator because of greater UV light exposure per unit time

Medical conditions

Chronic osteomyelitis sinus tracts, burn scars, chronic skin ulcers, xeroderma pigmentosum and human papillomavirus infection all increase risk.

Xeroderma pigmentosum, immunosuppression, other malignancies and previous nonmelanoma skin cancer all increase risk.

Nevi

No influence on risk

Nonfamilial dysplastic nevi, a large number of benign pigmented nevi, and giant pigmented congenital nevi confer increased risk. Nondysplastic nevi are markers for risk, not precursor lesions.

Occupation

Higher incidence in outdoor workers

Higher incidence in indoor workers, as well as those with higher education and income.

Previous history of skin cancer

36 to 52 percent chance of a new skin cancer of any kind within five years of index case

Previous melanoma is associated with increased risk.

Race

More common in whites

More common in whites

Skin type/ethnicity

Increased incidence in those with fair complexions; those who burn easily, tan poorly and freckle; those who have red, blonde or light brown hair; and those of Celtic ancestry

Increased incidence in those with fair complexions; those who burn easily, tan poorly and freckle; those who have red, blonde or light brown hair; and those of Celtic ancestry

Sun exposure

Cumulative

Single greatest risk factor; 80 percent of lifetime sun exposure is obtained before 18 years of age.

Probably does not influence risk

Episodic

Probably does not influence risk

Intense, intermittent exposure and blistering sunburns in childhood and adolescence are associated with increased risk.


PUVA = psoralen plus ultraviolet A.

Information from references 1 and 8 through 12.

TABLE 2   Risk Factors for Skin Cancer

View Table

TABLE 2

Risk Factors for Skin Cancer

Risk factor Nonmelanoma skin cancer Melanoma

Age

More common with increasing age

Peak frequency in early adulthood, but age-related incidence rises with increasing age.

Chemicals and exposures

Use of coal-tar products, tobacco and psoralens (e.g., PUVA therapy) increase risk.

Radiation exposure increases risk.

Family history

No influence on risk

Occurrence of melanoma in a first- or second-degree relative confers increased risk. Familial atypical mole–melanoma syndrome (FAMMS) confers even higher risk.

Gender

Substantially more common in males

Slight male predominance

Geographic location

Higher incidence in whites living near the equator because of greater ultraviolet (UV) light exposure per unit time

Higher incidence in whites living near the equator because of greater UV light exposure per unit time

Medical conditions

Chronic osteomyelitis sinus tracts, burn scars, chronic skin ulcers, xeroderma pigmentosum and human papillomavirus infection all increase risk.

Xeroderma pigmentosum, immunosuppression, other malignancies and previous nonmelanoma skin cancer all increase risk.

Nevi

No influence on risk

Nonfamilial dysplastic nevi, a large number of benign pigmented nevi, and giant pigmented congenital nevi confer increased risk. Nondysplastic nevi are markers for risk, not precursor lesions.

Occupation

Higher incidence in outdoor workers

Higher incidence in indoor workers, as well as those with higher education and income.

Previous history of skin cancer

36 to 52 percent chance of a new skin cancer of any kind within five years of index case

Previous melanoma is associated with increased risk.

Race

More common in whites

More common in whites

Skin type/ethnicity

Increased incidence in those with fair complexions; those who burn easily, tan poorly and freckle; those who have red, blonde or light brown hair; and those of Celtic ancestry

Increased incidence in those with fair complexions; those who burn easily, tan poorly and freckle; those who have red, blonde or light brown hair; and those of Celtic ancestry

Sun exposure

Cumulative

Single greatest risk factor; 80 percent of lifetime sun exposure is obtained before 18 years of age.

Probably does not influence risk

Episodic

Probably does not influence risk

Intense, intermittent exposure and blistering sunburns in childhood and adolescence are associated with increased risk.


PUVA = psoralen plus ultraviolet A.

Information from references 1 and 8 through 12.

When screening is performed, the examiner must systematically inspect the entire skin surface. The patient should completely disrobe and remove concealing cosmetics. Daylight is the ideal light source, but full-spectrum halogen light or combined incandescent light (which accentuates red tones) and fluorescent light (which accentuates blue and yellow tones) is also satisfactory.13 Photographs may improve the quality of documentation and detection of lesion changes over time.14

Identification and Treatment of Specific Skin Neoplasms

ACTINIC KERATOSES

Actinic keratoses, sometimes called solar keratoses, often arise on chronically sun-damaged body areas such as the face, ears, arms and hands. They may provide an indication of a person's cumulative ultraviolet light exposure and, therefore, that person's risk for all types of skin cancer. Actinic keratoses may also be associated with other exposures15  (Table 2).1,812

Actinic keratoses are often ill-defined and irregular, ranging from 1 mm to several centimeters in size. They may be macular or papular, and generally have a scaly appearance (Figure 1). Patients often have multiple lesions. The lesions are usually pale brown or flesh-colored but may be yellow, reddish-brown or even dark brown or black following trauma. The differential diagnosis for actinic keratoses includes benign inflammatory disorders with secondary reactive keratinocytic atypia, Bowen's disease (squamous cell carcinoma in situ), discoid lupus erythematosus, lichen planus and superficial basal cell carcinoma. The rate of malignant transformation of individual actinic keratoses to squamous cell carcinoma is less than one per 1,000 per year,16 but treatment of lesions is indicated to decrease the chance of progression to squamous cell carcinoma. Skin biopsy is occasionally required to rule out squamous cell carcinoma.

FIGURE 1.

Actinic keratoses. Note the scaly appearance of the multiple lesions. Lesions of actinic keratosis may be macular or papular.

View Large


FIGURE 1.

Actinic keratoses. Note the scaly appearance of the multiple lesions. Lesions of actinic keratosis may be macular or papular.


FIGURE 1.

Actinic keratoses. Note the scaly appearance of the multiple lesions. Lesions of actinic keratosis may be macular or papular.

Cryotherapy with liquid nitrogen is the treatment of choice for most cases of actinic keratosis. Curettage may also be used and may be used in conjunction with cryosurgery or electrodessication. Surgical excision is rarely required but may be useful in excluding squamous cell carcinoma as a possible cause in lesions that are larger than 0.5 cm in diameter.15

Chemical destruction of superficial lesions may be used when there are many lesions, particularly on the face and head. A pyrimidine antagonist that inhibits DNA synthesis, 5-fluorouracil (5-FU), is most commonly used. This agent is supplied in several topical formulations, including 1, 2 and 5 percent solutions and 1 and 5 percent creams. Areas other than the head and neck require the higher concentrations because of greater skin thickness. In conventional regimens, 5-FU is applied twice daily for two to five weeks. Adverse effects include true hypersensitivity, secondary bacterial and herpetic infection, and postinflammatory pigmentation changes. This therapy is often associated with significant discomfort related to an intense inflammatory response. Pulsed dosing regimens aimed at reducing skin irritation have met with mixed success.17 Topical corticosteroids may reduce inflammation but also make the treatment end point difficult to discern.18 Other therapies used occasionally for treatment of actinic keratoses include carbon dioxide laser, topical tretinoin, chemexfoliation (chemical peeling) and facial dermabrasion.

SQUAMOUS CELL CARCINOMA

Squamous cell carcinoma is the second most common skin cancer, comprising 20 percent of all cases of nonmelanoma skin cancer. This is the most common tumor in elderly patients, and it is usually the result of a high lifetime cumulative dose of solar radiation. However, other irritants and exposures may lead to squamous cell carcinoma (Table 2).1,812 Up to 60 percent of squamous cell carcinomas occur at the site of a previous actinic keratosis.19 Changes in an actinic keratosis that suggest evolution to squamous cell carcinoma include pain, erythema, ulceration, induration, hyperkeratosis and increasing size.

As many as 50 to 60 percent of squamous cell carcinomas occur on the head and neck (Figure 2). Other common sites include the hands and forearms, upper trunk and lower legs. Squamous cell carcinomas typically appear as exophytic tumors that may grow moderately rapidly over a period of months and range from a few millimeters to centimeters in size. They may appear nodular or papular, and may be reddish-brown, pink or flesh-colored. Larger squamous cell carcinomas may appear crusted, erythematous or eroded. In contrast to basal cell carcinoma, a definitive edge is difficult to demonstrate when a squamous cell carcinoma lesion is stretched.16

FIGURE 2.

Squamous cell carcinoma of the face.

View Large


FIGURE 2.

Squamous cell carcinoma of the face.


FIGURE 2.

Squamous cell carcinoma of the face.

The differential diagnosis of squamous cell carcinoma includes actinic keratosis, amelanotic melanoma, basal cell carcinoma, benign tumors, keratoacanthoma, healing traumatic wounds, spindle cell tumor and warts. Histologic confirmation by a full-thickness skin biopsy (incisional or excisional) is mandatory before definitive treatment. Well-differentiated lesions less than 2 cm in diameter can be treated with surgical excision, with a cure rate approaching 99 percent. Typically, an elliptical excision with margins of 4 to 6 mm is employed.19

Squamous cell carcinomas may grow aggressively and are associated with a 2 to 6 percent risk of metastasis. Risk factors for metastasis include poor cell differentiation, increasing lesion depth and location on the lip or ear. The most common locations for metastatic spread are the regional lymph nodes, lungs and liver. Once metastasis occurs, the five-year cure rate for squamous cell carcinoma is 34 percent. Recurrence and metastasis typically occur within three years of initial treatment.

Mohs' micrographic surgery involves gradual lesion excision using serial frozen section analysis and precise mapping of excised tissue until a tumor-free plane is reached. Mohs' micrographic surgery is used when tissue removal must be kept to a minimum for cosmetic reasons or to maximize function. It is the treatment of choice for difficult and high-risk squamous cell carcinomas, including lesions that are larger than 2 cm in diameter; located in areas where deep invasion is more likely or tumor extent is hard to assess, such as the nasolabial folds, eyelids and periauricular areas (facial “H zone”); rapidly growing; recurrent or incompletely excised; ill-defined; located in an area of previous irradiation; or located where perineural invasion is likely. Cure rates of 99 percent have been reported.20

Cryotherapy and the combination of curettage and desiccation are reserved for treatment of superficial tumors, lesions less than 2 cm in diameter and lesions located on the trunk and extremities. Radiation therapy may be employed when preservation of function and cosmesis are critical, when patients refuse surgery, when metastasis is present or when an adjunct to surgery is required for high-risk tumors. Because of the long-term risk of radiation-induced carcinoma, radiation therapy is used only in patients older than 60 years.16

BASAL CELL CARCINOMA

Basal cell carcinoma is the most common skin neoplasm. Basal cell carcinomas may be classified as one of six types: nodular, the most common type (Figure 3a); pigmented (Figure 3b); cystic; sclerosing or morpheaform (Figure 3c); superficial (Figure 3d); and nevoid. The sclerosing type may extend beyond clinically assessed borders and is the most difficult type to adequately treat. Basal cell carcinomas are usually located on the face or the backs of the hands. They typically grow slowly and generally spread only locally. Metastasis is quite rare.

FIGURE 3.

Common types of basal cell carcinoma. (A) Nodular; (B) pigmented; (C) sclerosing; (D) superficial. Note the characteristic rolled borders and telangiectasias.

View Large


FIGURE 3.

Common types of basal cell carcinoma. (A) Nodular; (B) pigmented; (C) sclerosing; (D) superficial. Note the characteristic rolled borders and telangiectasias.


FIGURE 3.

Common types of basal cell carcinoma. (A) Nodular; (B) pigmented; (C) sclerosing; (D) superficial. Note the characteristic rolled borders and telangiectasias.

While a preliminary diagnosis of basal cell carcinoma may be made on the basis of appearance, incisional or excisional biopsy is required for definitive diagnosis. Cure rates of 95 to 99 percent can be achieved for low-risk lesions using simple excision with margins of 2 to 5 mm.21,22 A lesion is considered low risk if it is less than 1.5 cm in diameter; has not previously been treated; is not in a difficult-to-treat area, like the H zone of the face; and is nodular or cystic.21

Treatment of basal cell carcinomas with cryotherapy can also be successful, but healing may take weeks, and success depends on the skill of the cryotherapist. Curettage with electrodesiccation or freezing may also be used for tumors less than 1.5 cm in diameter. These modalities are associated with lower cure rates when used to treat sclerosing and recurrent tumors.22 Mohs' micrographic surgery is the treatment of choice for most sclerosing basal cell carcinomas, as well as for large tumors and those located in areas that are difficult to treat. Radiation therapy produces cure rates of 90 to 95 percent but has the same limitations as those outlined for squamous cell carcinoma treatment.22 Other therapies used occasionally include oral retinoids; topical tretinoin; carbon dioxide and neodynium-YAG lasers; topical 5-FU; and, for inoperable and metastatic tumors, chemotherapy.2123

MALIGNANT MELANOMA

There are four types of malignant melanoma.18 The superficial spreading type is the most common among whites and accounts for 70 percent of all melanomas. It usually occurs in adults and may develop anywhere on the body but appears with increased frequency on the upper backs of both men and women and on the legs of women (Figure 4).

FIGURE 4.

Superficial spreading malignant melanoma.

View Large


FIGURE 4.

Superficial spreading malignant melanoma.


FIGURE 4.

Superficial spreading malignant melanoma.

Nodular melanoma (accounting for 15 to 30 percent of all melanomas) is a dome-shaped, pedunculated or nodular lesion that may occur anywhere on the body. It is commonly dark brown or reddish brown but may occasionally be amelanotic. Nodular melanomas tend to rapidly invade the dermis from the onset with no apparent horizontal growth phase. These tumors are frequently misdiagnosed, because they may resemble blood blisters, hemangiomas, dermal nevi or polyps (Figure 5).

FIGURE 5.

Nodular malignant melanoma.

View Large


FIGURE 5.

Nodular malignant melanoma.


FIGURE 5.

Nodular malignant melanoma.

Lentigo maligna melanoma (which accounts for 4 to 10 percent of all melanomas) originates from lentigo maligna. Untreated lentigo maligna tends to exhibit horizontal or radial growth with epidermal involvement for many years (often decades) before it enters the vertical growth phase and invades the dermis to become lentigo maligna melanoma. This change is often indicated clinically by the development of focal papular or nodular areas (Figure 6).

FIGURE 6.

Lentigo maligna melanoma.

View Large


FIGURE 6.

Lentigo maligna melanoma.


FIGURE 6.

Lentigo maligna melanoma.

Acral lentiginous melanoma (2 to 8 percent of all melanomas) occurs on the palmar and plantar surfaces, the digits and the subungual areas (Figure 7). Unlike other subtypes of melanoma, it has a similar incidence in all ethnic groups.

FIGURE 7.

Acral lentiginous melanoma.

View Large


FIGURE 7.

Acral lentiginous melanoma.


FIGURE 7.

Acral lentiginous melanoma.

Melanomas that do not fit easily into any of these subtypes are simply labeled malignant melanoma.

Evaluation of Pigmented Lesions

Common benign lesions that mimic melanoma include seborrheic keratoses, benign acquired nevi and solar lentigenes. Other lesions that mimic melanoma are more ominous. Large congenital nevi (greater than 20 cm in diameter) are clearly associated with an increased risk of melanoma,24 and controversy exists regarding the potential for malignant transformation in smaller congenital nevi. Lentigo maligna (Hutchinson's melanotic freckle), discussed above, is commonly located in sun-damaged areas on the heads and necks of elderly persons. Because lentigo maligna is considered by many authorities to be a melanoma in situ, prompt excision is generally indicated.

Atypical or dysplastic nevi may lead to melanoma. These macular to papular lesions may be present in great numbers in affected patients and up to 6 mm or larger in size. They have a cobblestone surface with a variable mixture of tan, brown, and red or pink coloration, and characteristically ill-defined borders (Figure 8). Dysplastic nevi with substantial asymmetry, excessive pigmentary variegation and focal black or gray areas suggestive of partial regression should be biopsied. In the atypical mole syndrome, an autosomal dominant familial disorder, affected persons have numerous dysplastic nevi and often develop melanoma at a young age. Patients with atypical mole syndrome require periodic screening and preventive education.25

FIGURE 8.

Dysplastic nevi.

View Large


FIGURE 8.

Dysplastic nevi.


FIGURE 8.

Dysplastic nevi.

Clinical application of the ABCD checklist may improve detection of suspicious lesions26  (Table 3). Although melanomas may lack one or more of these features, their presence, especially in combination, should raise suspicion of malignancy. The ABCD checklist has been reported to have a sensitivity of 92 to 100 percent and a specificity of 98 percent for the detection of melanoma.11  It may also be prudent to lower the threshold for biopsy when a patient is worried that a nevus may be cancerous or reports recent changes in the nevus such as increased size, alteration of shape or color, itching, burning, bleeding or pain. The revised seven-point checklist, which incorporates these findings, has a reported sensitivity of 79 to 100 percent (Table 4).6 Its low specificity of 30 to 37 percent reflects the fact that most melanomas are asymptomatic.6 Dermoscopic evaluation of suspicious lesions may also help clarify the need for biopsy. In dermoscopy, a hand-held microscope with a 10-power lens is pressed on the skin lesion after the application of oil. The presence or absence of subsurface features suggestive of melanoma guides the need for biopsy.27

TABLE 3

The ABCD Checklist for Detecting Cutaneous Melanoma

Checklist item Reassuring elements Nonreassuring elements

A = Asymmetry Suggestive of melanoma if the lesion is bisected and the halves are not identical

Symmetric (benign)

Asymmetric (malignant melanoma)

B = Border irregularity Suggestive of melanomaif the border is uneven or ragged

Borders are even (benign)

Borders are irregular (malignant melanoma)

C = Color variation Suggestive of melanoma if there is more than one shade of pigment

One shade/even color (benign)

Two or more shades/uneven color (malignant melanoma)

D = Diameter Suggestive of melanoma if the diameter is greater than 6 mm

Diameter < 6 mm (benign)

Diameter > 6 mm (malignant melanoma)


note: Biopsy should be strongly considered if one or more nonreassuring elements are present.

TABLE 3   The ABCD Checklist for Detecting Cutaneous Melanoma

View Table

TABLE 3

The ABCD Checklist for Detecting Cutaneous Melanoma

Checklist item Reassuring elements Nonreassuring elements

A = Asymmetry Suggestive of melanoma if the lesion is bisected and the halves are not identical

Symmetric (benign)

Asymmetric (malignant melanoma)

B = Border irregularity Suggestive of melanomaif the border is uneven or ragged

Borders are even (benign)

Borders are irregular (malignant melanoma)

C = Color variation Suggestive of melanoma if there is more than one shade of pigment

One shade/even color (benign)

Two or more shades/uneven color (malignant melanoma)

D = Diameter Suggestive of melanoma if the diameter is greater than 6 mm

Diameter < 6 mm (benign)

Diameter > 6 mm (malignant melanoma)


note: Biopsy should be strongly considered if one or more nonreassuring elements are present.

TABLE 4

Seven-Point Checklist for Suspected Malignant Melanoma

Major signs*

Change in size

Change in shape

Change in color

Minor signs

Inflammation

Crusting or bleeding

Sensory change

Diameter of 7 mm or more


*—One or more major signs: refer for expeditious biopsy; additional presence of one or more minor signs increases the possibility of melanoma.

—Three or four minor signs without a major sign: consider referral.

Information from Whited JD, Grichnik JM. Does this patient have a mole or a melanoma? JAMA 1998; 279:696–701.

TABLE 4   Seven-Point Checklist for Suspected Malignant Melanoma

View Table

TABLE 4

Seven-Point Checklist for Suspected Malignant Melanoma

Major signs*

Change in size

Change in shape

Change in color

Minor signs

Inflammation

Crusting or bleeding

Sensory change

Diameter of 7 mm or more


*—One or more major signs: refer for expeditious biopsy; additional presence of one or more minor signs increases the possibility of melanoma.

—Three or four minor signs without a major sign: consider referral.

Information from Whited JD, Grichnik JM. Does this patient have a mole or a melanoma? JAMA 1998; 279:696–701.

Diagnosis, Staging and Therapy

Biopsies for evaluation of suspected melanoma should generally be excisional. An elliptical excision that includes 1 to 2 mm of normal skin surrounding the lesion and extends to the subcutaneous tissue provides acceptable histopathologic margins. A larger margin is unnecessary and may entail an excessively wide definitive excision if melanoma is confirmed. Incisional and punch biopsies of the most visually concerning lesion segments, considered acceptable by some, may be problematic because the histologic diagnosis of melanoma depends on overall lesion architecture and because such areas may not contain the most histopathologically diagnostic tissue.28 Therefore, complete excision should be strongly considered even when the lesion is large or located in a cosmetically sensitive area.

Prognosis in patients with clinically localized disease is directly related to tumor thickness (Table 5).18,29 The prognosis is more favorable in women, in persons less than 50 years of age and for tumors that occur on an extremity (excluding the hands and feet). The five-year survival rate in patients with nodal spread is about 36 percent and drops to 5 percent in those with distant metastasis.6 Patients with melanoma proved by biopsy should be expeditiously referred to a dermatologist for treatment.

TABLE 5

Breslow's Microstages and Clark's Levels for Melanoma

Breslow's microstages Five-year survival (%)

Stage 1: < 0.76 mm

> 98

Stage 2: 0.76 to 1.49 mm

87 to 94

Stage 3: 1.50 to 3.99 mm

66 to 83

Stage 4: > 4.0 mm

< 50

Clark's levels Five-year survival (%)

Level I: Intraepidermal

> 99

Level II: Extends into the papillary dermis

95

Level III: Fills the papillary dermis

82

Level IV: Extends into the reticular dermis

71

Level V: Invades the subcutaneous tissue

49


Information from Habif TP. Clinical dermatology: a color guide to diagnosis and therapy. 3d ed. St. Louis: Mosby, 1996:898, and Goldstein BG, Goldstein AO. Practical dermatology. St. Louis: Mosby, 1992:132.

TABLE 5   Breslow's Microstages and Clark's Levels for Melanoma

View Table

TABLE 5

Breslow's Microstages and Clark's Levels for Melanoma

Breslow's microstages Five-year survival (%)

Stage 1: < 0.76 mm

> 98

Stage 2: 0.76 to 1.49 mm

87 to 94

Stage 3: 1.50 to 3.99 mm

66 to 83

Stage 4: > 4.0 mm

< 50

Clark's levels Five-year survival (%)

Level I: Intraepidermal

> 99

Level II: Extends into the papillary dermis

95

Level III: Fills the papillary dermis

82

Level IV: Extends into the reticular dermis

71

Level V: Invades the subcutaneous tissue

49


Information from Habif TP. Clinical dermatology: a color guide to diagnosis and therapy. 3d ed. St. Louis: Mosby, 1996:898, and Goldstein BG, Goldstein AO. Practical dermatology. St. Louis: Mosby, 1992:132.

Prevention of Skin Cancer

Primary prevention of skin cancer is based on increasing public awareness of the risks of sun exposure and providing patients with individualized guidance. Patients who are educated about risk factors for skin cancer are more likely to self-select for clinical screening30 and to bring malignant lesions to the attention of a health care provider.31  Family physicians can easily integrate education regarding “safe sun” guidelines into general preventive counseling (Table 6).1 While the role of sunscreens has been questioned, most evidence suggests that their correct use can lower the risk of skin cancer.32 Sufficient amounts must be applied at least 30 minutes before sun exposure, with reapplication after prolonged exposure or swimming. Most importantly, sunscreens will not be effective unless they are employed as only one element of a skin cancer prevention program.

TABLE 6

“Safe Sun” Guidelines for Prevention of Skin Cancer

Sun exposure during the peak ultraviolet-B (UV-B) hours should be avoided or minimized. The peak UV-B period is from 10 a.m. to 4 p.m.

Sunscreen with a solar protection factor (SPF) of at least 15 should be generously applied.

In addition to use of an appropriate sunscreen, persons should wear wide-brimmed hats, sunglasses and protective clothing (e.g., tightly woven fabrics and long-sleeved shirts) when sun exposure during peak UV-B hours cannot be avoided.

Deliberate sun tanning and use of tanning parlors should be avoided.


Information from Gloster HM, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22:217–26.

TABLE 6   “Safe Sun” Guidelines for Prevention of Skin Cancer

View Table

TABLE 6

“Safe Sun” Guidelines for Prevention of Skin Cancer

Sun exposure during the peak ultraviolet-B (UV-B) hours should be avoided or minimized. The peak UV-B period is from 10 a.m. to 4 p.m.

Sunscreen with a solar protection factor (SPF) of at least 15 should be generously applied.

In addition to use of an appropriate sunscreen, persons should wear wide-brimmed hats, sunglasses and protective clothing (e.g., tightly woven fabrics and long-sleeved shirts) when sun exposure during peak UV-B hours cannot be avoided.

Deliberate sun tanning and use of tanning parlors should be avoided.


Information from Gloster HM, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22:217–26.

Resources for patients and health care providers are listed in Table 7.

TABLE 7

Resources for Patients and Providers

American Academy of Family Physicians

“How to Prevent Skin Cancer” (patient education handout)

Web address: http://www.aafp.org/patientinfo/980915a.html

American Cancer Society

1599 Clifton Rd., NE

Atlanta, GA 30329

Telephone: 1–800–227–2345

Web address: www.cancer.org

The Skin Cancer Foundation

P.O. Box 561

Department SEC

New York, NY 10156

Telephone: 1–800-SKIN-490

www.skincancer.org/home

American Academy of Dermatology

930 N. Meacham Rd.

Schaumburg, IL 60173–4965

Telephone: 1–888–462–3376

Web address: www.aad.org

TABLE 7   Resources for Patients and Providers

View Table

TABLE 7

Resources for Patients and Providers

American Academy of Family Physicians

“How to Prevent Skin Cancer” (patient education handout)

Web address: http://www.aafp.org/patientinfo/980915a.html

American Cancer Society

1599 Clifton Rd., NE

Atlanta, GA 30329

Telephone: 1–800–227–2345

Web address: www.cancer.org

The Skin Cancer Foundation

P.O. Box 561

Department SEC

New York, NY 10156

Telephone: 1–800-SKIN-490

www.skincancer.org/home

American Academy of Dermatology

930 N. Meacham Rd.

Schaumburg, IL 60173–4965

Telephone: 1–888–462–3376

Web address: www.aad.org

The Authors

ANTHONY F. JERANT, M.D., is assistant professor and associate residency director in the Department of Family and Community Medicine at the University of California, Davis, School of Medicine, Sacramento. Previously he was a member of the family practice residency faculty at Eisenhower Army Medical Center, Fort Gordon, Ga. Dr. Jerant received his medical degree from Saint Louis University School of Medicine, St. Louis, Mo., and completed a family medicine residency at Madigan Army Medical Center, Fort Lewis, Wash.

JENNIFER T. JOHNSON, M.D., is a member of the teaching faculty at the Eisenhower Army Medical Center family practice residency program. Dr. Johnson obtained her medical degree at Texas Tech University Health Sciences Center School of Medicine, Lubbock. She completed a residency in family medicine at Madigan Army Medical Center.

CATHERINE DEMASTES SHERIDAN, M.D., is clinic commander of Buedingen Army Health Clinic in Buedingen, Germany. She obtained her medical degree at Northeastern Ohio Universities College of Medicine, Rootstown, and completed a residency in family medicine at Eisenhower Army Medical Center.

TIMOTHY J. CAFFREY, M.D., is a member of the family practice staff at the U.S. Army Health Clinic, Vicenza, Italy. He received his medical degree from Dartmouth Medical School, Hanover, N.H., and completed a family practice residency at Eisenhower Army Medical Center.

Address correspondence to Anthony F. Jerant, M.D., Assistant Professor of Clinical Family Medicine, Department of Family and Community Medicine, University of California, Davis, School of Medicine, 4860 Y St., Suite 2300, Sacramento, CA 95817. Reprints are not available from the authors.

REFERENCES

1. Gloster HM, Brodland DG. The epidemiology of skin cancer. Dermatol Surg. 1996;22:217–26.

2. Halder RM, Bridgeman-Shah S. Skin cancer in African Americans. Cancer. 1995;75:667–73.

3. Marks R. An overview of skin cancers. Incidence and causation. Cancer. 1995;75:607–12.

4. Balch CM. Cutaneous melanoma. Philadelphia: Lippincott, 1992:165–87.

5. Koh HK, Geller AC. Public health interventions for melanoma. Prevention, early detection, and education. Hematol Oncol Clin North Am. 1998;12:903–28.

6. Whited JD, Grichnik JM. Does this patient have a mole or a melanoma? JAMA. 1998;279:696–701.

7. Office of Disease Prevention and Health Promotion. Clinician's handbook of preventive services: put prevention into practice. Washington, D.C.: U.S. Department of Health and Human Services, 1994: 155.

8. Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol. 1995;22:853–7.

9. Pion IA, Rigel DS, Garfinkel L, Silverman MK, Kopf AW. Occupation and the risk of malignant melanoma. Cancer. 1995;75:637–44.

10. Berwick M, Halpern A. Melanoma epidemiology. Curr Opinion Oncol. 1997;9:178–82.

11. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Arch Dermatol. 1996;132:444–50.

12. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997;277:1439–44.

13. Kopf AW, Salopek TG, Slade J, Marghoob AA, Bart RS. Techniques of cutaneous examination of the skin. Cancer. 1995;75:684–90.

14. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust. 1997;167:191–4.

15. Barnaby JW, Stylels AR, Cockerell CJ. Actinic keratoses. Differential diagnosis and treatment. Drugs Aging. 1997;11:186–205.

16. Marks R. Squamous cell carcinoma. Lancet. 1996;347:735–8.

17. Epstein E. Does intermittent ”pulse” topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol. 1998;38:77–80.

18. Habif TP. Clinical dermatology: a color guide to diagnosis and therapy. 3d ed. St. Louis: Mosby, 1996:714–5.

19. Goldman GD. Squamous cell cancer: a practical approach. Semin Cutan Med Surg. 1998;17:80–95.

20. Nelson BR, Railan D, Cohen S. Mohs' micrographic surgery for nonmelanoma skin cancers. Clin Plastic Surg. 1997;24:705–18.

21. Pariser DM, Phillips PK. Basal cell carcinoma: when to treat it yourself, and when to refer. Geriatrics. 1994;49:39–44.

22. Goldberg LH. Basal cell carcinoma. Lancet. 1996;347:663–7.

23. Goldberg DP. Assessment and surgical treatment of basal cell skin cancer. Clin Plastic Surg. 1997;24:673–86.

24. Keller JM, Maize JC. The clinical and histological differential diagnosis of malignant melanoma. Semin Oncol. 1996;23:693–702.

25. Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol. 1995;32:479–94.

26. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin. 1985;35:130–51.

27. Rigel DS. Recent advances in diagnostic techniques. Skin Cancer Found J. 1998;16:36–7.

28. Salopek TG, Slade J, Marghoob AA, Rigel DS, Kopf AW, Bart RS, et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. I. Survey of biopsy practices of pigmented lesions suspected as melanoma. J Am Acad Dermatol. 1995;33:441–50.

29. Goldstein BG, Goldstein AO. Practical dermatology. St. Louis: Mosby, 1992:132.

30. Rivers JK, Gallagher RP. Public education projects in skin cancer. Experience of the Canadian Dermatology Association. Cancer. 1995;75:661–6.

31. Jones TP, Boiko PE, Piepkorn MW. Skin biopsy indications in primary care practice: a population-based study. J Am Board Fam Pract. 1996;9:397–404.

32. Naylor MF, Farmer KC. The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Arch Dermatol. 1997;133:1146–54.

Members of various medical faculties develop articles for “Practical Therapeutics.” This article is one in a series coordinated by the Department of Family and Community Medicine at Eisenhower Army Medical Center, Fort Gordon, Ga. Guest editor of the series is Ted D. Epperly, COL, MC, USA.


Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article